Skip to main content

Table 1 Characteristics of 271 patients with ductal carcinoma in situ (DCIS), with and without invasive breast cancer

From: Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer

  

DCIS

All patients

DCIS only

DCIS with invasive cancer

N

(%)

N

(%)

N

(%)

Total

271

(100.0)

120

(100.0)

151

(100.0)

Age at diagnosis, years

      

 <40

24

(8.9)

4

(3.3)

20

(13.2)

 40–49

90

(33.2)

43

(35.8)

47

(31.1)

 50–64

90

(33.2)

36

(30.0)

54

(35.8)

 ≥65

67

(24.7)

37

(30.8)

30

(19.9)

Year of breast cancer diagnosis

      

 2000–2003

226

(83.4)

97

(80.8)

129

(85.4)

 2004–2007

43

(15.9)

22

(18.3)

21

(13.9)

 2008–2011

2

(0.7)

1

(0.8)

1

(0.7)

Race

      

 Missing

5

(1.8)

2

(1.7)

3

(2.0)

 Hispanic

10

(3.7)

4

(3.3)

6

(4.0)

 Non-Hispanic (NH) white

199

(73.4)

81

(67.5)

118

(78.1)

 NH black

4

(1.5)

3

(2.5)

1

(0.7)

 NH Asian/Pacific Islander

53

(19.6)

30

(25.0)

23

(15.2)

Socioeconomic status

      

 Missing

30

(11.1)

19

(15.8)

11

(7.3)

 1 (Lowest)

4

(1.5)

2

(1.7)

2

(1.3)

 2

15

(5.5)

8

(6.7)

7

(4.6)

 3

23

(8.5)

9

(7.5)

14

(9.3)

 4

40

(14.8)

10

(8.3)

30

(19.9)

 5 (Highest)

159

(58.7)

72

(60.0)

87

(57.6)

Hormone receptors

      

 Missing

12

(4.4)

0

0

12

(7.9)

 Either ER or PR positive

137

(50.6)

65

(54.2)

72

(47.7)

 Both ER and PR negative

122

(45.0)

55

(45.8)

67

(44.4)

Stage

      

 Missing

4

(1.5)

0

0

4

(2.6)

 Stage 0

120

(44.3)

120

(100.0)

0

0

 Stage I

69

(25.5)

0

0

69

(45.7)

 Stage II

69

(25.5)

0

0

69

(45.7)

 Stage III

8

(3.0)

0

0

8

(5.3)

 Stage IV

1

(0.4)

0

0

1

(0.7)

Grade

      

 Missing

2

(0.7)

1

(0.8)

1

(0.7)

 1

56

(20.7)

27

(22.5)

29

(19.2)

 2

130

(48.0)

57

(47.5)

73

(48.3)

 3

83

(30.6)

35

(29.2)

48

(31.8)

HER2 gain

      

 No gain

182

(67.2)

83

(69.2)

99

(65.6)

 Gain

89

(32.8)

37

(30.8)

52

(34.4)

  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2